BioNTech SE - ADR vs United Parcel Service Inc — how do they compare? BioNTech SE - ADR trades at $90.35 (market cap $22.86B), while United Parcel Service Inc trades at $114.26 (market cap $96.62B). The key difference: United Parcel Service Inc is far larger — about 4.2× BioNTech SE - ADR's market cap, and United Parcel Service Inc pays a 5.77% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | UPS | |
|---|---|---|
Market Cap | $22.86B | $96.62B |
Sector | Health | Industrials |
52-Week High | $119.34 | $120.00 |
52-Week Low | $83.89 | $82.58 |
Enterprise Value | $6.53B | $119.48B |
Volume | — | 2,288,643 |
Dividend Yield | — | 5.77% |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
UPS stock trades at $112.89, up 0.37% today, with a bullish technical signal and consistent earnings beats. The company maintains solid profitability with a 5.94% net margin and 33.41% ROE, though revenue has declined from $100.3B in 2022 to $88.66B in 2025. Recent news highlights a $48 million investment in healthcare logistics and AI-driven efficiency improvements, while analyst sentiment is mixed with a consensus price target of $112.
The outlook for UPS is balanced; cost controls and strategic investments support margins, but revenue pressure and competitive threats from Amazon pose risks. The stock's valuation at a P/E of 18.27 is reasonable, yet growth headwinds and dividend sustainability concerns warrant caution. Upside depends on execution in logistics innovation and reversing top-line declines.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →